• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Iovance Biotherapeutics downgraded by Citizens JMP

    5/9/25 8:42:44 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IOVA alert in real time by email
    Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform
    Get the next $IOVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOVA

    DatePrice TargetRatingAnalyst
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    10/24/2024$17.00Buy
    UBS
    7/29/2024$19.00 → $10.00Overweight → Neutral
    Piper Sandler
    11/20/2023$12.00Buy
    Goldman
    9/18/2023$40.00 → $18.00Overweight
    Barclays
    5/30/2023$11.00 → $17.00Equal Weight → Overweight
    Wells Fargo
    3/27/2023$11.00Equal Weight
    Wells Fargo
    1/27/2023$11.00 → $14.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $IOVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

      SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C-144-01 study of lifileucel monotherapy in patients with advanced melanoma, and a poster on study design for lifileucel in frontline advanced non-small cell lung cancer, will be presented at the 2025

      4/23/25 4:15:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on April 17, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 297,600 shares of Iovance's common stock to fifty new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13

      4/18/25 5:30:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Iovance Biotherapeutics Inc.

      10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      5/8/25 5:15:56 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      5/8/25 4:05:33 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Iovance Biotherapeutics Inc.

      DEFA14A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      4/28/25 5:05:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcpeak Merrill A bought $2,287,500 worth of shares (250,000 units at $9.15), increasing direct ownership by 356% to 320,150 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 7:52:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dukes Iain D. bought $292,800 worth of shares (32,000 units at $9.15), increasing direct ownership by 145% to 54,000 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 4:21:48 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rothbaum Wayne P. bought $45,750,000 worth of shares (5,000,000 units at $9.15) (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 4:11:20 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

      SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today. "I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team," stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance. "Dan has been instrumental in building and leading cell therapy comm

      2/10/25 7:00:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IOVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Regulatory Officer Puri Raj K. converted options into 8,334 shares and covered exercise/tax liability with 2,509 shares, increasing direct ownership by 3% to 201,252 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/18/25 8:30:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Interim CEO & General Counsel Vogt Frederick G

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:06:49 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Regulatory Officer Puri Raj K.

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:06:26 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      11/14/24 4:50:30 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      10/18/24 8:38:16 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      3/19/24 5:19:45 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Financials

    Live finance-specific insights

    See more
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

      SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming

      2/18/25 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

      Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lym

      11/7/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iovance Biotherapeutics downgraded by Citizens JMP

      Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform

      5/9/25 8:42:44 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Iovance Biotherapeutics with a new price target

      UBS initiated coverage of Iovance Biotherapeutics with a rating of Buy and set a new price target of $17.00

      10/24/24 6:22:38 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Iovance Biotherapeutics from Overweight to Neutral and set a new price target of $10.00 from $19.00 previously

      7/29/24 7:40:13 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

      For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

      2/16/24 3:48:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care